These agents extend beyond endometrial protection by actively modulating progesterone resistance and rebalancing intracrine estrogen synthesis through downregulation of aromatase and 17β-HSD1 and upregulation of 17β-HSD2, thereby mitigating key mechanisms sustaining lipedema progression. This evidence concerns the gene CYP19A1 and Lipedema.